Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular

Kuang-Hua Chen1, Shihui Liu2, Clinton E Leysath1

  • 1From the Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, Bethesda, Maryland 20892-3202 and.

Insights

Researchers engineered anthrax toxin

Area of Science:

  • Microbiology
  • Molecular Biology
  • Toxicology

Background:

  • Anthrax toxin's protective antigen (PA) binds cellular receptors to deliver enzymatic moieties.
  • Capillary morphogenesis protein 2 (CMG2) and tumor endothelial marker 8 (TEM8) are known PA receptors.
  • PA domain 4 (PAD4) mediates PA receptor interactions.

Purpose of the Study:

  • To develop PA variants with selective binding to CMG2.
  • To investigate the role of PA residue isoleucine 656 in receptor binding specificity.

Main Methods:

  • Phage display selections using CMG2-bound magnetic beads.
  • Site-directed mutagenesis of PA residue 656.
  • Functional assays using cell lines and receptor-deficient mice.

Main Results:

  • PA residue isoleucine 656 is critical for TEM8 binding but less so for CMG2 binding.
  • PA variants I656Q and I656V showed reduced TEM8 activity but retained CMG2 activity.
  • Mutant preference for CMG2 over TEM8 was confirmed in cellular and animal models.

Conclusions:

  • PA residue 656 is a key determinant for distinguishing CMG2 and TEM8 binding.
  • Engineered PA variants demonstrate selective CMG2 binding, offering potential for targeted applications.